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Abstract
BACKGROUND—Prostaglandin E2 (PGE2) has been shown to modulate angiogenesis and
tumour progression via the E-series prostanoid-2 (EP2) receptor. Endometrial adenocarcinomas
may be exposed to endogenous PGE2 and exogenous PGE2, present at high concentration in
seminal plasma.
METHODS—This study investigated fibroblast growth factor 2 (FGF2) mRNA expression and
cell signalling in response to seminal plasma or PGE2, using an endometrial adenocarcinoma
(Ishikawa) cell line stably expressing the EP2 receptor (EP2 sense cells) and endometrial
adenocarcinoma explants.
RESULTS—Seminal plasma and PGE2 induced a significant up-regulation of FGF2 expression
in EP2 sense but not parental untransfected Ishikawa (wild-type) cells (P < 0.05). These effects
were inhibited by co-treatment with EP2 receptor antagonist or inhibitors of protein kinase A, c-
Src, epidermal growth factor receptor (EGFR) kinase or extracellular signal-regulated kinase
(ERK) signalling. The treatment of EP2 sense cells with seminal plasma induced cAMP
accumulation and phosphorylation of c-Src, EGFR kinase and ERK via the EP2 receptor. Finally,
seminal plasma and PGE2 significantly increased FGF2 mRNA expression in endometrial
adenocarcinoma tissue explants via the EP2 receptor (P < 0.05).
CONCLUSIONS—Seminal plasma and PGE2 can similarly activate FGF2 expression and EP2
receptor signalling in endometrial adenocarcinoma cells. These data highlight the potential for
seminal plasma exposure to facilitate tumorigenesis–angiogenesis in endometrial
adenocarcinomas in vivo.
© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and
Embryology. All rights reserved.
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Introduction
Prostaglandins (PGs) are bioactive lipids that have a wide range of physiological and
pathological functions in the female reproductive tract. They are synthesized by the actions
of cyclooxygenase (COX) enzymes and terminal prostanoid synthase enzymes that are
specific to the prostanoids that they produce (Narumiya et al., 1999; Jabbour and Sales,
2004).
There are two major isoforms of the COX enzymes (COX-1 and COX-2), which are
regulated by a range of paracrine and autocrine mechanisms. COX-1 is generally considered
to be constitutively expressed, whereas COX-2 is rapidly induced by growth factors,
oncogenes and other tumorigenic factors (Smalley and DuBois, 1997; Vane et al., 1998).
Recent evidence shows that both isoforms are up-regulated in several cancers and play a
central role in tumorigenesis, including those of the reproductive tract (Hwang et al., 1998;
Jabbour et al., 2001; Kitamura et al., 2002; Sales et al., 2002a; Gupta et al., 2003; Sales and
Jabbour, 2003). PGE2 exerts its effect via G-protein-coupled receptors termed E-series
prostanoid receptors (EPs). Four EP subtypes have been described, termed EP1–EP4, which
use alternate signalling pathways (Narumiya et al., 1999; Sales and Jabbour, 2003).
PGE2 biosynthesis and E-series prostanoid-2 (EP2) receptor expression and signalling are
significantly elevated in endometrial adenocarcinoma tissues compared with normal
endometrium (Jabbour et al., 2001). In a recent study, we have shown that PGE2 via the EP2
receptor can promote the expression and release of a potent pro-angiogenic factor, vascular
endothelial growth factor (VEGF), from endometrial adenocarcinoma cells (Sales et al.,
2004). These data suggest an autocrine/paracrine regulation of neoplastic endometrial cell
function by PGE2 via the EP2 receptor.
In addition to the regulation of endometrial function by PGE2 produced endogenously by
COX enzymes, endometrial tissue may also be exposed to exogenous PGE2 from seminal
plasma. Seminal plasma is characterized by a very high PG content with PGE2 levels of ~70
μg/ml, at least 1000-fold higher than those measured in normal endometrium (Templeton et
al., 1978; Smith et al., 1981; Lumsden et al., 1983; Bendvold et al., 1987). Emerging
evidence suggests that seminal plasma constituents can travel into the endometrium and
regulate gene expression (Robertson, 2005). This has prompted the suggestion that, in
sexually active women, endometrial pathologies associated with aberrant prostanoid
receptor expression may be enhanced following exposure to seminal plasma (Jabbour and
Sales, 2004).
This study was designed to investigate the role of seminal plasma in the modulation of
neoplastic endometrial cell function via the EP2 receptor using the Ishikawa endometrial
adenocarcinoma cell line stably expressing the EP2 receptor (EP2 sense cells) and
endometrial adenocarcinoma explants. We found that seminal plasma and PGE2 could up-
regulate the expression of the potent mitogenic/pro-angiogenic gene, fibroblast growth
factor 2 (FGF2) via the EP2 receptor in EP2 sense cells. This elevation in FGF2 gene
expression is mediated via the EP2 receptor in a cAMP-, c-Src-, epidermal growth factor
receptor (EGFR)- and extracellular signal-regulated kinase (ERK)-dependent manner.
Furthermore, using endometrial adenocarcinoma tissue explants, we have shown that the
EP2 receptor and FGF2 co-localize within the glandular epithelial compartment and have
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confirmed that seminal plasma and PGE2 can up-regulate the expression of FGF2 ex vivo in
endometrial adenocarcinoma biopsy explants via the EP2 receptor.
Materials and methods
Culture medium was purchased from Invitrogen (Paisley, Scotland, UK). Fetal calf serum
(FCS) and penicillin–streptomycin were obtained from PAA Laboratories (Middlesex, UK).
FGF2 goat polyclonal antibody (sc-1360), EGFR rabbit polyclonal antibody (sc-03), p-tyr
(PY99) agarose conjugate and myc (9E10) agarose conjugate were purchased from Autogen
Bioclear (Wiltshire, UK). Anti-phospho-p44/42 ERK (9101) and anti-p44/42 ERK (9102)
were obtained from Cell Signaling Technologies (New England Biolabs, Hertfordshire,
UK). EP2 receptor rabbit polyclonal antibody (CAY-101750) was purchased from Axxora
(Nottingham, UK). Alkaline phosphatase secondary antibody, indomethacin, phosphate-
buffered saline (PBS), bovine serum albumin (BSA) and PGE2 were purchased from Sigma
(Dorset, UK). The enhanced chemofluorescence (ECF) system was obtained from
Amersham Biosciences (Little Chalfont, Bucks, UK). PD98059, AG1478, PP2, 4-cyano-3-
methylisoquinoline (4C3MQ), Anti-c-Src (p-Tyr 418) rabbit polyclonal antibody and
Protein A/G agarose were purchased from Merck Biosciences (Nottingham, UK). Doses of
chemical inhibitors and dilutions of antibody were determined empirically by titration using
the manufacturer’s guidelines.
Patients and tissue collection
Endometrial adenocarcinoma tissue was collected from women who were undergoing
hysterectomy, and who had been prediagnosed with adenocarcinoma of the uterus.
Hysterectomy specimens were collected from the operating theatre, placed on ice and
opened by a gynaecological pathologist with minimal delay. Small samples of
adenocarcinoma tissue (5 mm–3 cm) were placed in medium on ice and removed to the
laboratory for culture. The diagnosis of adenocarcinoma was confirmed histologically by a
specialist pathologist in all cases. The grading of the degree of differentiation was carried
out according to the criteria defined by Federation Internationale Obstetrics et Gynaecologie
(FIGO; Pecorelli et al., 1999). Pooled human seminal plasma was obtained from healthy
young men involved in the ongoing semen donor programme. Seminal plasma was isolated
from the pooled ejaculate by Percoll density gradient centrifugation at 500 × g for 20 min.
The seminal plasma was pooled and stored at -70°C. The PGE2 concentration in the pooled
seminal plasma was determined by enzyme-linked immunosorbent assay (ELISA) as
described previously (Sales et al., 2002b) and found to be 43.5 ± 8.7 μg/ml. The seminal
plasma was used on the cells at a 1:250 dilution. At this dilution, the PGE2 present in the
pooled ejaculate corresponds comparably with the concentration of PGE2 used in this study
(100 nM). At this dilution, seminal plasma has been reported to exert no adverse effect on
HeLa cell viability (Jeremias et al., 1997). Ethical approval was obtained from Lothian
Research Ethics Committee, and written informed consent was obtained from all subjects
before tissue collection.
Cell culture
Human Ishikawa endometrial adenocarcinoma cells (European Collection of Cell Culture,
Centre for Applied Microbiology, Wiltshire, UK) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) nutrient mixture F-12 with glutamax-1 and pyridoxine
supplemented with 10% FCS and 1% antibiotics (stock 500 IU penicillin and 500 μg/ml
streptomycin) at 37°C and 5% CO2 (v/v). Stable EP2 transfectant cells (EP2 sense cells)
were maintained under the same conditions with the addition of a maintenance dose of 200
μg/ml G418.
Battersby et al. Page 3
Hum Reprod. Author manuscript; available in PMC 2009 June 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
EP2 receptor cell characterization
EP2 receptor amplification, transfection into Ishikawa cells and characterization of the EP2
sense cell line used in this study have been described previously (Sales et al., 2004). The
EP2 sense cell line was found to express a 4.2 ± 1.8-fold greater level of EP2 receptor than
parental untransfected Ishikawa cells (wild-type). This level of EP2 receptor expression in
EP2 sense cells is comparable with the levels of EP2 receptor observed in endometrial
adenocarcinoma biopsy tissues (Sales et al., 2004).
Taqman quantitative RT–PCR
FGF mRNA expression in EP2 sense and wild-type Ishikawa cells or endometrial
adenocarcinomas was measured by quantitative RT–PCR analysis. For expression in EP2
sense and wild-type Ishikawa cells, 2.5 × 105 cells were seeded in six-well plates and
allowed to attach and grow for 24 h. Cells were subsequently serum-starved overnight in
medium containing 8.4 μM indomethacin. Medium was removed and replaced with DMEM
(in the presence of 10% FCS and 8.4 μM indomethacin) containing vehicle, a 1:250 dilution
of seminal plasma or 100 nM PGE2, and cells were incubated for 2, 4, 6 and 8 h at 37°C. In
subsequent experiments, a 6-h time point was chosen, and EP2 sense cells were incubated
with seminal plasma or PGE2 following pretreatment with inhibitors of protein kinase A
(PKA; 4C3MQ, 1 μM), c-Src (PP2, 10 μM), EGFR kinase (AG1478, 100 nM) or mitogen-
activated protein kinase kinase (MEK; PD98059, 50 μM) for 30 min or the EP2 receptor
antagonist AH6809 (10 μM) for 2 min, and RNA was extracted from cells using Total RNA
Isolation Reagent (TRIR; Abgene, Epsom, UK) according to the manufacturer’s
instructions.
To investigate the effect of seminal plasma on FGF2 expression in intact endometrial
adenocarcinoma tissue, biopsy explants (n = 6; two well-differentiated and four moderately
differentiated adenocarcinomas) were finely minced and serum-starved overnight at 37°C in
the presence of 8.4 μM indomethacin. Samples were divided into four portions and pre-
incubated for 30 min in vehicle (two portions) or PD98059, or 2 min in AH6809. Tissue was
subsequently treated for 6 h with vehicle, a 1:250 dilution of seminal plasma or 100 nM
PGE2. Tissue was homogenized in 1 ml of TRIR, and RNA was extracted according to the
manufacturer’s protocol. Quantified RNA samples were reverse transcribed, and quantitative
RT–PCR was performed as described previously (Sales et al., 2004). The sequence of the
FGF2-specific primers and probe are as follows: forward: 5′-
CCGACGGCCGCGTTGAC-3′; reverse: 5′-GACACAACTCCTCTCTCTT-3′ and probe:
5′-FAM-AGAAGAGCGACCCTCACATAMRA-3′. The ribosomal 18S primers and probe
sequences are as follows: forward: 5′-CGGCTACCACATCCAAGGAA-3′; reverse: 5′-
GCTGGAATTACCGCGGCT-3′ and probe (VIC labelled): 5′-
TGCTGGCACCAGACTTGCCCTC-3′ (Sales et al., 2004; Milling Smith et al., 2006). The
expression of FGF2 was normalized for RNA loading for each sample using the 18S rRNA
as an internal standard. Results are expressed relative to a sample of cDNA from normal
endometrium included in every PCR as an internal standard. Fold increase in FGF2
expression was determined by dividing the relative expression of FGF2 in seminal plasma or
PGE2-treated samples by the level of expression in vehicle-treated samples at the same time
points.
Cyclic AMP assay
Cyclic AMP accumulation was determined in response to treatment with seminal plasma at a
dilution of 1:250 in the absence or presence of inhibitors of cell signalling. EP2 sense cells
(2.5 × 105) were plated in six-well plates and allowed to attach overnight. The following day
the cells were starved by overnight treatment with serum-free medium containing 8.4 μM
indomethacin, and thereafter, the cells were incubated for 1 h at 37°C in serum-free medium
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containing 1 mM 3-isobutyl-1-methylxanthine (Sigma) and 8.4 μM indomethacin in the
presence or absence of inhibitors of PKA (4C3MQ, 1 μM), c-Src (PP2, 10 μM), EGFR
kinase (AG1478, 100 nM) or MEK (PD98059, 50 μM) or the EP2 receptor antagonist
AH6809 (10 μM) for 2 min. Cells were then stimulated with a 1:250 dilution of seminal
plasma for the time indicated in the legend to figure 2A or left unstimulated. Following
stimulation, cells were lysed in 0.1 M HCl, and cAMP concentration was determined by
ELISA using a cAMP kit (Biomol, Affiniti, Exeter, UK) according to the manufacturer’s
protocol. Concentrations were normalized to the protein concentration of the lysate
measured by the method of Lowry (Bio-Rad, Hemel Hempstead, UK).
Phosphorylated ERK, c-Src and EGFR studies
For studies of ERK phosphorylation, 2.5 × 105 cells were seeded in six-well plates, and for
c-Src and pEGFR studies, 3 × 106 cells were seeded in 10-cm dishes. On the following day,
the cells were washed with PBS and incubated in serum-free culture medium containing
penicillin/streptomycin and 8.4 μM indomethacin for at least 16 h. Cells were then
pretreated with specific chemical inhibitors of PKA (4C3MQ, 1 μM), c-Src (PP2, 10 μM),
EGFR kinase (AG1478, 100 nM) or MEK (PD98059, 50 μM) for 1 h before stimulation
with seminal plasma at a dilution of 1:250. The EP2 receptor antagonist (AH6809, 10 μM)
was added simultaneously with the seminal plasma treatment. After stimulation with
seminal plasma, cells were washed with ice-cold PBS and proteins were extracted with
protein lysis buffer [150 mM NaCl, 50 mM Tris–HCl (pH 7.4), 10 mM EDTA, 0.6%
nonidet-P40 and 10% glycerol containing protease inhibitors]. Insoluble material was
pelleted by centrifugation at 19 000 × g for 20 min at 4°C. The clarified lysate was removed
to a new tube, and protein content was quantified as described above.
Transient cell transfections and immunoprecipitation
The role of c-Src, EGFR and ERK in seminal plasma-mediated cell signalling was
investigated further by the use of dominant negative (DN) isoforms targeted against MEK,
EGFR and c-Src. The DN-MEK and DN-EGFR cDNA constructs were provided by
Professor Zvi Naor (Department of Biochemistry, University of Tel Aviv, Israel). The DN-
MEK was generated as described previously (Seger et al., 1994; Jaaro et al., 1997) by
mutation of lysine 97 to alanine to yield a catalytically inactive enzyme. The myc-tagged
ERK mitogen-activated protein kinase construct and DN-c-Src construct was obtained from
Professor Robert Millar (MRC Human Reproductive Sciences Unit, Edinburgh, UK). DN-
SRC was generated by mutating lysine 295 to methionine to generate a kinase-dead enzyme
as described previously (Davidson et al., 2004). The DN-EGFR construct was produced by
mutating lysine 721 to alanine as described previously (Benard et al., 2001). EP2 sense cells
seeded overnight in 6-cm dishes (7.5 × 106 per dish) were exposed to 2.5 μg of a myc-
tagged ERK and 2.5 μg of DN-SRC, DN-EGFR, DN-MEK or control plasmid (pcDNA3;
Invitrogen) in the presence of 30 μl of SuperFect (Qiagen, Crawley, UK) in a total volume
of 1.2 ml of medium for 3 h and then cultured overnight in complete medium. Thereafter,
cells were incubated overnight in serum-free medium containing 8.4 μM indomethacin and
subsequently treated with vehicle, a 1:250 dilution of seminal plasma or seminal plasma in
the presence of AH6809 for 2 min. Cells were lysed as described above, and myc-tagged
ERK or phospho-tyrosine (p-Tyr) were isolated by immunoprecipitation. Briefly, equal
amounts of protein were incubated with myc-antibody or p-Tyr antibody conjugated to
protein A agarose beads overnight at 4°C with gentle rotation. Beads were washed
extensively with lysis buffer, and immune complexes were then solubilized in Laemmli
buffer (125 mM Tris–HCl pH 6.8, 4% sodium dodecyl sulphate (SDS), 5% 2-
mercaptoethanol, 20% glycerol and 0.05% bromophenol blue) then boiled for 5 min.
Thereafter, solutes were subjected to Western blot analysis as described below.
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Western blot analysis
For ERK studies, 20 μg of protein was loaded for each sample. Proteins were resolved on 4–
12% Bis-Tris gels (Nupage, Invitrogen) and transferred onto polyvinylidene difluoride
membrane (Millipore, Watford, UK). Membranes were blocked for 1 h at 25°C in 4% BSA
diluted in TBST (50 mM Tris–HCl, 150 mM NaCl and 0.05% v/v Tween-20) and incubated
overnight at 4°C with anti-phospho-p44/42 ERK, anti-p44/42 ERK, c-Src or EGFR primary
antibodies at a dilution of 1:1000. Thereafter, blots were washed and incubated with alkaline
phosphatase-conjugated secondary antibodies at a dilution of 1:40 000. Immunore-active
proteins were visualized by the ECF system according to the manufacturer’s instructions.
Specific proteins were revealed, quantified and normalized to total protein expression using
Typhoon 9400 PhosphorImager and ImageQuant TL software (Molecular Dynamics,
Amersham Biosciences). Fold increase in protein expression was determined by dividing the
relative level of phosphorylated protein following treatment by the level in vehicle-treated
controls. Additionally, phosphorylated cSrc and EGFR blots were normalized against light-
chain immunoglobulin G (IgG) on the same blots.
Immunohistochemistry and confocal laser microscopy
EP2 receptor and FGF2 protein expression were co-localized in endometrial
adenocarcinomas (n = 12; four moderate, four well-differentiated and four poorly
differentiated adenocarcinomas) by dual immunofluorescence immunohistochemistry.
Tissue sections were prepared as described previously and blocked using 5% normal horse
serum diluted in PBS. Optimal dilution of antibody was determined by titration on serial
sections. Subsequently, sections were incubated with goat anti-FGF2 antibody at a dilution
of 1:80 for 18 h at 4°C. Control sections were incubated with equivalent concentration of
normal goat IgG. Thereafter, sections were washed with PBS and incubated with
biotinylated horse anti-goat (DAKO; Dako Corp., High Wycombe, UK) followed by
incubation with the fluorochrome streptavidin 488 Alexafluor (Molecular Probes, Eugene,
OR, USA) diluted 1:200 in PBS. Sections were re-blocked with 5% normal goat serum
diluted in PBS and incubated with rabbit anti-EP2 receptor antibody at a dilution of 1:100 at
4°C for 18 h. Control sections were incubated with equivalent concentration of rabbit IgG.
Thereafter, the sections were washed in PBS and incubated with the fluorochrome
streptavidin 546 Alexafluor (Molecular Probes) diluted 1 in 200 in PBS at 25°C for 20 min.
Sections were counterstained with 1:2000 dilution of To-Pro2 (Molecular Probes) and
mounted in permafluor (Immunotech-Coulter), coverslipped, visualized and photographed
as described previously (Sales et al., 2005).
Statistics
Data were subjected to statistical analysis with analysis of variance (ANOVA) and Fisher’s
protected least significant difference tests (Statview 4.0; Abacus Concepts, Piscataway, NJ,
USA) and statistical significance accepted when P < 0.05.
Results
Seminal plasma and PGE2 induce FGF2 expression via activation of EP2 receptor
signalling
Wild-type Ishikawa cells and EP2 sense cells were treated with seminal plasma (Figure 1A)
or 100 nM PGE2 (Figure 1B) for 2, 4, 6 and 8 h. A significant increase in FGF2 mRNA
expression was observed in EP2 sense cells after 6 h of treatment with seminal plasma or
PGE2 compared with vehicle-treated cells (5.2 ± 0.9- and 4.6 ± 2.3-fold increase for seminal
plasma and PGE2, respectively; P < 0.005 and P < 0.05; data are expressed as mean ± SEM).
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However, no such increase in FGF2 expression was observed in wild-type cells treated with
seminal plasma (Figure 1A) or PGE2 (Figure 1B).
Because FGF2 expression was unaltered by the treatment of wild-type Ishikawa cells with
either seminal plasma or PGE2 within the 8-h time frame, subsequent experiments were
performed using EP2 sense cells alone. The co-treatment of EP2 sense cells with AH6809,
4C3MQ, PP2, AG1478 or PD98059 significantly reduced the expression of FGF2 induced
by seminal plasma (Figure 1C; P < 0.05) or PGE2 (Figure 1D; P < 0.05).
Seminal plasma promotes cAMP accumulation via the EP2 receptor
The incubation of EP2 sense cells with seminal plasma for 5, 10 or 15 min induced a
significant time-dependent increase in cAMP accumulation compared with untreated cells
(Figure 2A; 269.6± 30.7, 448.3± 14.2 and 621.4± 261.1 pmoles cAMP/mg protein for 5, 10
and 15 min, respectively compared with 11.7 + 5.4 pmoles cAMP/mg protein for untreated
cells at 0 min; P < 0.01). cAMP levels were significantly reduced in the presence of the EP2
receptor antagonist (Figure 2B; P < 0.05). There was no significant difference in cAMP
accumulation in EP2 sense cells in response to seminal plasma in the presence of 4C3MQ,
PP2, AG1478 or PD98059 (Figure 2B).
Seminal plasma induces activation of ERK phosphorylation via the EP2 receptor
Following serum starvation of EP2 sense cells and in the absence of ligand or growth
factors, minimal basal levels of ERK phosphorylation were observed (Figure 3A, time zero).
The treatment of EP2 sense cells with the panel of chemical inhibitors on their own showed
no significant alteration to the basal levels of ERK phosphorylation observed following
serum starvation at time zero (data not shown); however, the co-treatment of EP2 sense cells
with seminal plasma and the chemical inhibitors significantly inhibited ERK
phosphorylation in response to treatment with seminal plasma for 2 min (Figure 3B; P <
0.05).
The treatment of empty vector-transfected EP2 sense cells with seminal plasma for 2 min
resulted in a significant phosphorylation of ERK compared with vehicle-treated cells (Figure
3C). This seminal plasma-induced elevation in ERK phosphorylation was inhibited by the
co-treatment of empty vector-transfected EP2 sense cells with AH6809 or by the co-
transfection of cells with DN-SRC, DN-EGFR or DN-MEK cDNAs (Figure 3C; P < 0.05).
Seminal plasma induces phosphorylation of c-Src and EGFR via the EP2 receptor
The phosphorylation of c-Src (Figure 4A) and EGFR (Figure 4B) was significantly
increased following treatment of EP2 sense cells with seminal plasma (P < 0.05). This
seminal plasma-induced phosphorylation of c-Src and EGFR was abolished by the co-
incubation of EP2 sense cells with AH6809, 4C3MQ and PP2. However, the co-incubation
of EP2 sense cells with AG1478 reduced the seminal plasma-induced phosphorylation of
EGFR but not c-Src, suggesting that c-Src phosphorylation is upstream of EGFR
phosphorylation. These data are in agreement with our previous observations for PGE2
signalling via the EP2 receptor (Sales et al., 2004) and demonstrate that seminal plasma
activates EP2 receptor signalling in a similar manner to that proposed for endogenously
secreted PGE2.
EP2 receptor and FGF2 co-localize in endometrial adenocarcinoma
Laser confocal immunofluorescence microscopy showed the EP2 receptor (red channel) and
FGF2 (green channel) were co-localized (merged, yellow) in the neoplastic epithelial cells
of poorly, moderately and well-differentiated endometrial adenocarcinoma tissues, with
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minimal stromal cell immunoreactivity observed (Figure 5). The substitution of the primary
antibody with a control IgG from the host species resulted in the loss of the specific
immunostaining.
Seminal plasma and PGE2 induce FGF2 expression in endometrial adenocarcinoma
explants
Seminal plasma and PGE2 treatment induced a 3.1 ± 0.4- and 2.2 ± 0.2-fold increase in
FGF2 mRNA expression, respectively (P < 0.05). The pretreatment of tissue explants with
AH6809 significantly reduced the seminal plasma and PGE2-induced elevation in FGF2
(Figure 6; P < 0.05).
Discussion
COX enzymes, prostanoids and their receptors are now established as major factors involved
in reproductive tract pathology (Jabbour et al., 2001; Sales and Jabbour, 2003; Jabbour and
Sales, 2004). COX-1 and COX-2, together with the EP2 receptor, are up-regulated in
reproductive tract carcinomas, including carcinoma of the endometrium (Tong et al., 2000;
Jabbour et al., 2001; Ferrandina et al., 2002) and have been shown to up-regulate the
expression of tumorigenic and angiogenic genes such as Ang-1 and Ang-2 (Tsujii et al.,
1998; Sales et al., 2002a) and VEGF (Gupta et al., 2003; Sales et al., 2004) and down-
regulate the production of anti-angiogenic genes (Perchick and Jabbour, 2003). Moreover,
PGs have been shown to up-regulate COX-2 expression and PG biosynthesis, thereby
establishing a positive feedback loop to amplify the angiogenic and tumorigenic signal
(Tjandrawinata et al., 1997; Jabbour et al., 2005; Sales et al., 2005).
The EP2 receptor is a Gαs-coupled seven-transmembrane receptor, which largely initiates
intracellular signalling via the cAMP-dependent PKA second messenger system (Regan,
2003). In endometrial adenocarcinomas, EP2 receptor signalling to cAMP is elevated
compared with normal tissue (Jabbour et al., 2001), indicating a possible autocrine/paracrine
regulation of neoplastic endometrial cell function via the PGE2–EP2–PKA axis. Indeed,
utilizing the endometrial adenocarcinoma cell model system overexpressing the EP2
receptor to the levels observed in endometrial adenocarcinomas (EP2 sense cells), we have
previously ascertained a role for PGE2-mediated activation of EP2 receptor signalling in the
promotion of angiogenic factor release via the cAMP-, c-Src- and EGFR-mediated
phosphorylation of ERK (Sales et al., 2004).
It is well established that PGE2 is present at ~10 000-fold higher concentration in seminal
plasma than that produced locally at the site of inflammation, and at least 1000-fold higher
than normal endometrium (Templeton et al., 1978; Smith et al., 1981; Lumsden et al., 1983;
Bendvold et al., 1987). The reported concentration in the seminal plasma of humans for
PGE2 and 19-R hydroxy PGE2 (a selective agonist for EP2 receptor) are 70 μg/ml and 250
μg/ml, respectively (Taylor and Kelly, 1975; Templeton et al., 1978; Bendvold et al., 1987),
~20-fold greater than that of PGF2α (Bendvold et al., 1987). Although it has been previously
thought that the cervix may provide a barrier to the passage of seminal plasma into the
uterine cavity, there is now increasing evidence that the effects of seminal plasma extend to
the uterus, with in vivo studies demonstrating that active seminal plasma constituents are
carried, together with sperm, into the higher tract facilitated by rapid and sustained
peristaltic contractions of the uterus (Robertson, 2005).
In this study, we have demonstrated for the first time that seminal plasma can activate
intracellular signalling in endometrial adenocarcinoma cells via the EP2 receptor. The data
reported herein demonstrate that the seminal plasma can activate the c-Src, EGFR and ERK
pathways in endometrial adenocarcinoma cells (EP2 sense), in a similar manner to PGE2 via
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the EP2 receptor (Sales et al., 2004), because c-Src, EGFR and ERK phosphorylation in EP2
sense cells were inhibited by an EP2 receptor antagonist (AH6809). Although the EP2
receptor antagonist AH6809 was previously reported to be an antagonist of the EP1
receptor, a study by Woodward et al. (1995) has shown that AH6809 acts as a potent
antagonist of the EP2 receptor with substantial competition for PGE2 at concentrations up to
10 μM (Woodward et al., 1995), and PGF2α at >100 μM (Abramovitz et al., 2000). We
failed to detect any EP1 receptor and found no difference in the levels of EP3, EP4 or FP
receptors in Ishikawa wild-type and EP2 sense cells (data not shown) and thus interpret the
actions of AH6809 in this study as being an antagonist of the EP2 receptor.
ERK is a key signalling mechanism involved in the control of gene transcription and
regulates many processes such as cellular transformation and growth. Our previous data
(Sales et al., 2004) demonstrate that the PGE2-mediated activation of ERK via the EP2
receptor occurs via the cAMP- and c-Src-mediated transactivation of the EGFR. In the
earlier study, we showed that a cell-permeable cAMP analogue, dibutryl cAMP, could
transphosphorylate the EGFR and phosphorylate ERK in a similar manner to PGE2 via the
EP2 receptor in EP2 sense cells; however, the ability of EGF to phosphorylate the EGFR
and ERK was independent of cAMP and c-Src (Sales et al., 2004). In this study, we show
that seminal plasma can also transphosphorylate the EGFR and phosphorylate ERK in a
similar manner to PGE2, via the EP2 receptor. From these data and our previous
observations of cell signalling in the EP2 sense cell line, it would appear that the
phosphorylation of c-Src precedes that of EGFR, because both chemical inhibitors of c-Src
and EGFR kinase inhibited EGFR phosphorylation; however, only the inhibitor of c-Src
inhibited c-Src phosphorylation. As the inhibitor of MEK failed to inhibit either c-Src or
EGFR phosphorylation, this implies that c-Src and EGFR phosphorylation precedes that of
ERK phosphorylation. These data are consistent with evidence from several studies that
support the sequence of G-protein-coupled receptor signalling to downstream ERK via the
c-Src-mediated transactivation of the EGFR (Luttrell et al., 1999; Pierce et al., 2001; Pai et
al., 2002; Buchanan et al., 2003; Sales et al., 2004; Sales et al., 2005). These observations
indicate that this pathway can be activated by endogenously synthesized PGs, and following
exposure to exogenous prostanoids such as those present in seminal plasma.
FGF2 is a potent mitogenic and angiogenic factor, causing endothelial cell proliferation and
migration, extracellular matrix degradation and modulation of adhesion factors (Presta et al.,
2005). FGF2 expression is elevated in endometrial carcinoma, and it has been suggested to
promote the vascularization and invasiveness of carcinomas (Yoshida et al., 2002; Billottet
et al., 2004). Moreover, FGF2 overexpression in endomentrial adenocarcinoma cells can
promote tumour growth when implanted s.c. in nude mice (Giavazzi et al., 2003). This study
has demonstrated that seminal plasma and PGE2 can up-regulate the expression of FGF2
mRNA in EP2 sense cells, but not wild-type Ishikawa cells, and endometrial
adenocarcinoma tissues. Furthermore, we have shown that this seminal plasma- and PGE2-
mediated expression of FGF2 occurs via the EP2 receptor following the sequential
activation of cAMP-dependent PKA, c-Src, EGFR kinase and ERK signalling.
Thus, pathologies of the endometrium, associated with an elevation in the expression of
prostanoid receptors, may be exacerbated by exposure to seminal plasma. This study has
demonstrated a mechanism whereby seminal plasma may promote endometrial carcinoma in
sexually active women via up-regulation of gene expression of potent growth factors such as
FGF2. The data presented herein also highlight the potential advantage of combining COX
enzyme inhibitors together with EP2 receptor antagonists or EGFR or ERK signalling
pathway inhibitors as therapeutic agents in endometrial adenocarcinoma. These agents
would target the actions of both endogenously produced PGs and the exogenous prostanoids
present in seminal plasma.
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Figure 1.
Fibroblast growth factor 2 (FGF2) expression in response to seminal plasma and
prostaglandin E2 (PGE2). FGF2 mRNA expression in wild-type and E-series prostanoid-2
(EP2) sense cells measured by real-time RT–PCR after the treatment of cells for 2, 4, 6 and
8 h with a 1:250 dilution of (A) seminal plasma (SP; b is significantly different from a, P <
0.005) or (B) 100 nM PGE2; b is significantly different from a (P < 0.05). FGF2 mRNA
expression in EP2 sense cells treated for 6 h with (C) SP or (D) PGE2 in the absence or
presence of the EP2 receptor antagonist (AH6809) or chemical inhibitors of protein kinase A
(4C3MQ), c-Src (PP2), EGFR kinase (AG1478) or mitogen-activated protein kinase (MEK)
(PD98059). b and c are significantly different from a (P < 0.05); c is significantly different
from b (P < 0.05). Data are shown as mean ± SEM from three independent experiments.
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Figure 2.
cAMP accumulation in response to seminal plasma. (A) E-Series prostanoid-2 (EP2) sense
cells were treated with a 1:250 dilution of seminal plasma for 5, 10 and 15 min or left
untreated (0 min). b is significantly different from a (P < 0.01). (B) EP2 sense cells were
treated with seminal plasma for 15 min in the absence/presence of the EP2 receptor
antagonist (AH6809) or chemical inhibitors of protein kinase A (4C3MQ), c-Src (PP2),
EGFR kinase (AG1478) or MEK (PD98059). b is significantly different from a (P < 0.05); c
is significantly different from a and b (P < 0.05). All data are shown as mean ± SEM from
three independent experiments.
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Figure 3.
Extracellular signal-regulated kinase (ERK) phosphorylation in E-series prostanoid-2 (EP2)
sense cells in response to seminal plasma. (A) ERK phosphorylation in EP2 sense cells
treated with a 1: 250 dilution of seminal plasma for 0–3 and 5 min. (B) ERK
phosphorylation in EP2 sense cells treated with seminal plasma for 2 min in the absence/
presence of the EP2 receptor antagonist (AH6809) or chemical inhibitors of protein kinase A
(4C3MQ), c-Src (PP2), EGFR kinase (AG1478) or MEK (PD98059). b is significantly
different from a (P < 0.05). (C) ERK phosphorylation in EP2 sense cells co-transfected with
a myc-tagged ERK cDNA construct together with a dominant negative cDNA isoform
targeted against c-Src (lane 4), the EGFR (lane 5), MEK (lane 6) or empty vector (lanes 1–
3) and stimulated with seminal plasma for 2 min either alone (lanes 2, 4–6) or in the
presence of AH6809 (lane 3). The tagged ERK construct was immunoprecipitated with an
anti-myc-antibody and immunoblotted. ERK phosphorylation levels are shown as mean ±
SEM from three independent experiments. b and c are significantly different from a (P <
0.05); c is significantly different from b (P < 0.05). Data are presented as representative
blots together with semi-quantitative analysis of ERK phosphorylation shown as mean ±
SEM from three independent experiments. b and c are significantly different from a (P <
0.05); c is significantly different from b (P < 0.05).
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Figure 4.
Phosphorylation of c-Src and epidermal growth factor receptor (EGFR). (A) E-Series
prostanoid-2 (EP2) sense cells were treated with a 1:250 dilution of seminal plasma for 2
min in the absence/presence of the EP2 receptor antagonist (AH6809) or chemical inhibitors
of protein kinase A (4C3MQ), c-Src (PP2), EGFR kinase (AG1478) or mitogen-activated
protein kinase kinase (MEK) (PD98059). Cell lysates were immunoprecipitated with an
anti-phosphotyrosine antibody and immunoblotted for phosphorylated c-Src. (B)
Immunoblots were stripped and reprobed for EGFR phosphorylation. The figure shows a
representative blot together with semi-quantitative analysis of c-Src or EGFR
phosphorylation shown as mean ± SEM from three independent experiments; b is
significantly different from a (P < 0.05).
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Figure 5.
Confocal immunofluorescent localization of E-series prostanoid-2 (EP2) receptor and
fibroblast growth factor 2 (FGF2) in endometrial adenocarcinoma. Localization of the site of
expression of the EP2 receptor (red; left panel), FGF2 (green; central panel) and co-
localization of EP2 receptor and FGF2 (merged yellow; right panel) in human endometrial
adenocarcinoma. P, poorly differentiated; M, moderately differentiated and W, well-
differentiated adenocarcinomas; inset, negative control section.
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Figure 6.
Effect of seminal plasma and prostaglandin E2 (PGE2) on fibroblast growth factor 2 (FGF2)
mRNA expression in endometrial adenocarcinoma. Real-time RT–PCR analysis of FGF2
mRNA expression in endometrial adenocarcinoma tissue treated with a 1:250 dilution of
seminal plasma (lane 2) or 100 nM PGE2 (lane 5) alone or in the presence of the E-series
prostanoid-2 receptor antagonist (AH6809; lanes 3 and 6 for seminal plasma and PGE2,
respectively). Data are shown as mean ± SEM from three independent experiments; b is
significantly different from a (P < 0.05).
Battersby et al. Page 18
Hum Reprod. Author manuscript; available in PMC 2009 June 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
